Trials

| CRISPR Medicine | This is an overview of articles on trials

Investigational New Drug (IND) Update – Sickle...

Jan. 13, 2021

This week’s IND update looks at two distinct gene-editing strategies for sickle cell disease, both of which are set to enter clinical trials soon...

Gene-Editing IND and Pre-clinical Update

Dec. 23, 2020

Update on Allogene Therapeutics off-the-shelf CAR-T cancer therapies. This week’s gene-editing update looks at an investigational new drug (IND)...

Severe Sickle Cell Disease, SCD, (GPH101)
Sponsors:
Graphite Bio

Pre-clinical

Phase I

Phase II

Phase III

Gene-Editing Clinical Trial Update

Dec. 16, 2020

In this week’s clinical update, we look at three clinical-stage CRISPR-engineered cell therapies that are under development for the treatment of acute...

Multiple Myeloma, MM, (ALLO-605)
Sponsors:
Allogene Therapeutics, Inc.

Pre-clinical

Phase I

Phase II

Phase III

CRISPR Therapy Turns a Corner With First Cures In...

Dec. 9, 2020

Just 8 years after the development of CRISPR-Cas technology, Vertex Pharmaceuticals and CRISPR Therapeutics share positive clinical data for their ex...

Pre-clinical Development CRISPR Update

Dec. 3, 2020

Last week, we bought you our first IND update for a selection of gene-editing therapies currently under development for blood disorders. This week, we...

Acute Myeloid Leukaemia, AML, (NCT04614636)
Sponsors:
Fate Therapeutics, Inc

Pre-clinical

Phase I

Phase II

Phase III